Dentithecamides A-H, Diacylated Zoanthoxanthin Derivatives with PAX3-FOXO1 Inhibitory Activity from the Hydroid Dentitheca habereri.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of natural products"
DOI: 10.1021/acs.jnatprod.2c00246
Abstract: Chemical investigation of the marine hydroid Dentitheca habereri led to the identification of eight new diacylated zoanthoxanthin alkaloids, named dentithecamides A-H (1-8), along with three previously reported analogues, zoamides B-D (9-11). The structures of compounds… read more here.
Keywords: dentitheca habereri; hydroid dentitheca; diacylated zoanthoxanthin; pax3 foxo1 ... See more keywords
Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies
Sign Up to like & getrecommendations! Published in 2020 at "Modern Pathology"
DOI: 10.1038/s41379-020-00719-0
Abstract: Alveolar Rhabdomyosarcoma (ARMS) is an aggressive pediatric cancer with about 80% of cases characterized by either a t(1;13)(p36;q14) or t(2;13)(q35;q14), which results in the formation of the fusion oncogenes PAX7-FOXO1 and PAX3-FOXO1, respectively. Since patients… read more here.
Keywords: detection; foxo1; rhabdomyosarcoma; fusion ... See more keywords
Dependence of PAX3-FOXO1 chromatin occupancy on ETS1 at important disease-promoting genes exposes new targetable vulnerability in Fusion-Positive Rhabdomyosarcoma
Sign Up to like & getrecommendations! Published in 2024 at "Oncogene"
DOI: 10.1038/s41388-024-03201-2
Abstract: Rhabdomyosarcoma (RMS), a malignancy of impaired myogenic differentiation, is the most common soft tissue pediatric cancer. PAX3-FOXO1 oncofusions drive the majority of the clinically more aggressive fusion-positive rhabdomyosarcoma (FP-RMS). Recent studies have established an epigenetic… read more here.
Keywords: pax3 foxo1; foxo1 chromatin; disease promoting; pax3 ... See more keywords
Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3–FOXO1 rhabdomyosarcoma
Sign Up to like & getrecommendations! Published in 2025 at "Cell Death Discovery"
DOI: 10.1038/s41420-025-02787-0
Abstract: Rhabdomyosarcoma (RMS) is an aggressive soft tissue sarcoma with myogenic features affecting children and adolescents. The high-risk fusion-positive RMS subtype (FP-RMS), driven by the oncogenic chimeric transcription factor PAX3–FOXO1, shows 5-year overall survival not exceeding… read more here.
Keywords: inhibition; pax3 foxo1; tumor; neddylation inhibition ... See more keywords
Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-98322-z
Abstract: B7-H3 (also known as CD276) is associated with aggressive characteristics in various cancers. Meanwhile, in alveolar rhabdomyosarcoma (ARMS), PAX3-FOXO1 fusion protein is associated with increased aggressiveness and poor prognosis. In the present study, we explored… read more here.
Keywords: myogenic differentiation; expression; pax3 foxo1; pax3 ... See more keywords
Entinostat as a combinatorial therapeutic for rhabdomyosarcoma
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-66545-5
Abstract: Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. For the alveolar subtype (ARMS), the presence of the PAX3::FOXO1 fusion gene and/or metastases are strong predictors of poor outcome. Metastatic PAX3::FOXO1+ ARMS often responds… read more here.
Keywords: pax3 foxo1; combinatorial therapeutic; rhabdomyosarcoma; entinostat combinatorial ... See more keywords
New dual inducible cellular model to investigate temporal control of oncogenic cooperating genes
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-71227-3
Abstract: The study of cooperating genes in cancer can lead to mechanistic understanding and identifying potential therapeutic targets. To facilitate these types of studies, we developed a new dual-inducible system utilizing the tetracycline- and cumate-inducible systems… read more here.
Keywords: cooperating genes; pax3 foxo1; model; new dual ... See more keywords
PAX3-FOXO1 escapes miR-495 regulation during muscle differentiation
Sign Up to like & getrecommendations! Published in 2019 at "RNA Biology"
DOI: 10.1080/15476286.2018.1564464
Abstract: ABSTRACT Pax3 plays an essential role in myogenesis. Previously, we found a tumor-signature chimeric fusion RNA, PAX3-FOXO1 also present during muscle differentiation, raising the possibility of its physiological role. Here we demonstrated that the fusion… read more here.
Keywords: fusion; muscle differentiation; pax3 foxo1; pax3 ... See more keywords
PAX3-FOXO1 Drives Targetable Cell State-Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma.
Sign Up to like & getrecommendations! Published in 2025 at "Cancer research"
DOI: 10.1158/0008-5472.can-25-0315
Abstract: PAX3-FOXO1, an oncogenic transcription factor, drives a particularly aggressive subtype of rhabdomyosarcoma (RMS) by enforcing gene expression programs that support malignant cell states. Here, we showed that PAX3-FOXO1+ RMS cells exhibit altered pyrimidine metabolism and… read more here.
Keywords: pax3 foxo1; pyrimidine; cell states; foxo1 ... See more keywords
Abstract 4630: Characterizing oncogene addiction in alveolar rhabdomyosarcoma reveals novel strategies for combination therapy
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4630
Abstract: Rhabdomyosarcoma is the most common soft tissue sarcoma in children. The aggressive alveolar subtype (aRMS) is characterized by chromosomal translocations, most often a t(2;13) resulting in the expression of the oncogenic fusion protein PAX3-FOXO1 which… read more here.
Keywords: protein; combination; rhabdomyosarcoma; combination therapy ... See more keywords
Abstract 5867: Identification of novel inhibitors of the PAX3-FOXO1 oncogenic driver in rhabdomyosarcoma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-5867
Abstract: Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood, representing 8% of all childhood tumors. The most aggressive subtype of RMS is associated with chromosomal translocations creating a fusion transcription factor, most… read more here.
Keywords: rhabdomyosarcoma; pax3 foxo1; foxo1 oncogenic; oncogenic driver ... See more keywords